Related references
Note: Only part of the references are listed.New strategies for the treatment of advanced-stage Hodgkin's lymphoma
Volker Diehl et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2007)
The AP1-dependent secretion of galectin-1 by Reed - Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
Przemyslaw Juszczynski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma
S. Hohaus et al.
ANNALS OF ONCOLOGY (2007)
Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma:: A study from the Groupe d'Etude des Lymphomes de l'Adulte
Rene-Olivier Casasnovas et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL
April Chiu et al.
BLOOD (2007)
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma
MK Gandhi et al.
CLINICAL CANCER RESEARCH (2006)
Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: Potential for a prognostic factor
MR Weihrauch et al.
CANCER RESEARCH (2005)
From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential
D Re et al.
BLOOD (2005)
Epstein-Barr virus-associated Hodgkin's lymphoma
MK Gandhi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma
NA Marshall et al.
BLOOD (2004)
Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma
FJ Giles et al.
LEUKEMIA RESEARCH (2004)
Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma
M Fischer et al.
LEUKEMIA (2003)
Long-term cause-specific mortality of patients treated for Hodgkin's disease
BMP Aleman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
V Diehl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Polymorphisms in the interleukin-10 and interferon gamma genes in Hodgkin lymphoma
LR Munro et al.
LEUKEMIA & LYMPHOMA (2003)
The role of interleukin 13 in classical Hodgkin lymphoma
BF Skinnider et al.
LEUKEMIA & LYMPHOMA (2002)
Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues
E Maggio et al.
ANNALS OF ONCOLOGY (2002)
New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group
A Josting et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease
C Buri et al.
BLOOD (2001)
The role of chemokines in Hodgkin's disease
J Teruya-Feldstein et al.
LEUKEMIA & LYMPHOMA (2000)
Poor clinical outcome of patients with Hodgkin's Disease and elevated interleukin-10 serum levels - Clinical significance of interleukin-l0 serum levels for Hodgkin's disease
H Bohlen et al.
ANNALS OF HEMATOLOGY (2000)
Share Paper
